Sebastiani Ventures Enters Definitive Agreement to Acquire Artificial Intelligence Company, Evokai Creative Labs Inc.

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES.

VANCOUVER, BC / ACCESSWIRE / September 23, 2022 / Sebastiani Ventures Corp. ("Sebastiani" or the "Company") (TSX-V:SBS.H), further to its press release issued August 17, 2022, is pleased to announce that it has entered into a definitive business combination agreement (the "Merger Agreement") dated effective September 22, 2022, pursuant to which it will acquire (the "Acquisition"), through its newly formed subsidiary, all the issued and outstanding share capital of EvokAI Creative Labs Inc. ("EvokAI").

The Acquisition will constitute a reverse takeover under the policies of the TSX Venture Exchange (the "Exchange"). Upon closing, it is anticipated that Sebastiani will graduate to Tier 2 of the Exchange as a technology issuer and will change its name to EvokAI Creative Labs Inc.

EvokAI is a MedTech AI-powered company incorporated in the British Virgin Islands on July 7, 2021, and headquartered in Allschwil, Switzerland. EvokAI is dedicated to the development of transformational and innovative technologies for the modern healthcare sector. It deploys machine learning models to search medical data and uncover insights to help improve health outcomes, patient experiences, drug development, preclinical and clinical decisions and provide more accurate diagnoses. EvokAI tailors its AI algorithms across the whole healthcare system, from hospitals, private clinics, research institutions, pharmaceutical companies, contract research organizations, to medical professionals, patients, healthy individuals aiming at preventing any kind of disease and beyond, protecting the aging genome.

EvokAI has shown significant advances during the last months, bridging the gap between neuroscience and artificial intelligence, tackling one of the most severe neurodegenerative diseases, Alzheimer's, which is becoming more common as the general population gets older and lives longer, and recently broadening its scope by revolutionizing Parkinson´s Disease analysis and treatment. Entering the MedTech field, this unique novel wireless medical device accurately analyzes the magnitude of movement disorders and the effectiveness of treatments for Parkinson's disease and other movement disorders, a smart device to improve patients' quality of life and support doctors in their work.